全文获取类型
收费全文 | 8169篇 |
免费 | 534篇 |
国内免费 | 40篇 |
专业分类
耳鼻咽喉 | 63篇 |
儿科学 | 132篇 |
妇产科学 | 111篇 |
基础医学 | 1080篇 |
口腔科学 | 233篇 |
临床医学 | 851篇 |
内科学 | 1625篇 |
皮肤病学 | 110篇 |
神经病学 | 953篇 |
特种医学 | 580篇 |
外科学 | 1470篇 |
综合类 | 31篇 |
一般理论 | 1篇 |
预防医学 | 247篇 |
眼科学 | 187篇 |
药学 | 463篇 |
中国医学 | 14篇 |
肿瘤学 | 592篇 |
出版年
2024年 | 9篇 |
2023年 | 89篇 |
2022年 | 195篇 |
2021年 | 399篇 |
2020年 | 203篇 |
2019年 | 248篇 |
2018年 | 308篇 |
2017年 | 230篇 |
2016年 | 360篇 |
2015年 | 380篇 |
2014年 | 464篇 |
2013年 | 493篇 |
2012年 | 772篇 |
2011年 | 705篇 |
2010年 | 421篇 |
2009年 | 369篇 |
2008年 | 566篇 |
2007年 | 497篇 |
2006年 | 436篇 |
2005年 | 412篇 |
2004年 | 335篇 |
2003年 | 320篇 |
2002年 | 225篇 |
2001年 | 33篇 |
2000年 | 24篇 |
1999年 | 35篇 |
1998年 | 32篇 |
1997年 | 27篇 |
1996年 | 6篇 |
1995年 | 17篇 |
1994年 | 12篇 |
1993年 | 10篇 |
1992年 | 6篇 |
1991年 | 10篇 |
1990年 | 4篇 |
1989年 | 9篇 |
1988年 | 7篇 |
1987年 | 7篇 |
1986年 | 6篇 |
1985年 | 5篇 |
1984年 | 6篇 |
1983年 | 6篇 |
1981年 | 4篇 |
1978年 | 3篇 |
1977年 | 3篇 |
1976年 | 5篇 |
1975年 | 4篇 |
1970年 | 4篇 |
1969年 | 3篇 |
1966年 | 4篇 |
排序方式: 共有8743条查询结果,搜索用时 15 毫秒
1.
2.
3.
Distinct genetic alterations and luminal molecular subtype in nested variant of urothelial carcinoma
4.
Stefan Scholz Florian Koerber Kinga Meszaros Rosa Maya Fassbender Bernhard Ultsch Robert R. Welte Wolfgang Greiner 《Vaccine》2019,37(12):1692-1701
Introduction
Invasive meningococcal disease (IMD) is a severe disease mainly affecting infants and young children. The most common serogroup causing IMD in Germany is the serogroup type B Neisseria meningitidis (MenB). The aim of the present study is to estimate the economic burden of MenB-related IMD in Germany.Method
A bottom-up, model-based costing approach has been used to calculate the diagnose- and age-specific yearly lifetime costs of a hypothetical cohort of MenB-related IMD cases. Direct costs contain the treatment cost for the acute phase of the disease, long-term sequelae, costs for rehabilitation, and public health response. Indirect costs are calculated for the human-capital approach and the friction-cost approach considering productivity losses of patients or parents for the acute phase and long-term sequelae. Publicly available databases from the Federal Statistical Office, the SOEP panel data set, literature, and expert opinion were used as data sources. All future costs beyond the reference year of 2015 were discounted at 3%.Results
The total costs for the hypothetical cohort (343 patients) from a societal perspective are €19.6 million (€57,100/IMD case) using the friction-cost approach and €58.8 million (€171,000/IMD case) using the human-capital approach. Direct costs amount to €18.6 million or €54,300 €/case. Sequelae are responsible for 81% of the direct costs/case.Discussion
The elevated costs/MenB-related IMD case reflect the severity of the disease. The total costs are sensitive to the productivity-loss estimation approach applied. MenB is an uncommon but severe disease; The costs/case reflect the severity of the disease and is within the same magnitude as for human papilloma virus infections. The available literature on sequelae is due to the uncommonness limited and heterogeneous. 相似文献5.
6.
7.
8.
9.
Lesley A. Inker Morgan E. Grams Andrew S. Levey Josef Coresh Massimo Cirillo John F. Collins Ron T. Gansevoort Orlando M. Gutierrez Takayuki Hamano Gunnar H. Heine Shizukiyo Ishikawa Sun Ha Jee Florian Kronenberg Martin J. Landray Katsuyuki Miura Girish N. Nadkarni Carmen A. Peralta Dietrich Rothenbacher Mark Woodward 《American journal of kidney diseases》2019,73(2):206-217
10.
Erythropoietin(EPO) is one of the most successful biopharmaceuticals in history and is used for treating anemia of different origins. However, it became clear that EPO could also work in a neuroprotective, antiapoptotic, antioxidative, angiogenetic and neurotropic way. It causes stimulation of cells to delay cell apoptosis, especially in the central nervous system. In rodent models of focal cerebral ischemia, EPO showed an impressive reduction of infarct size by 30% and improvement of neurobehavioral outcome by nearly 40%. A large animal model dealing with ischemia and reperfusion of the spinal cord showed that EPO could reduce the risk of spinal cord injury significantly. In addition, some clinical studies tested whether EPO works in real live clinical settings. One of the most promising studies showed the innocuousness and improvements in follow-up, outcome scales and in infarct size, of EPO-use in humans suffering from ischemic stroke. Another study ended unfortunately in a negative outcome and an increased overall death rate in the EPO group. The most possible reason was the involvement of patients undergoing simultaneously systemic thrombolysis with recombinant tissue plasminogen activator. An experimental study on rats demonstrated that administration of EPO might exacerbate tissue plasminogen activator-induced brain hemorrhage without reducing the ischemic brain damage. This case shows clearly how useful animal models can be to check negative side effects of a treatment before going into clinical trials. Other groups looked in human trials at the effects of EPO on the outcome after ischemic stroke, relation to circulating endothelial progenitor cells, aneurysmal subarachnoid hemorrhage, traumatic brain injury, hemoglobin transfusion thresholds and elective first-time coronary artery bypass surgery. Most of the results were positive, but are based mostly on small group sizes. However, some of the most neglected facts when focusing on experimental setups of ischemia of the central nervous system are issues like age and comorbidities. It might be extremely worthy to consider these points for future projects, because EPO might influence all these factors. 相似文献